DADC
VYGR icon

D.A. Davidson & Co’s Voyager Therapeutics VYGR Stock Holding History

D.A. Davidson & Co’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,500
Closed -$255K – 1176
2018
Q3 		$255K Sell
13,500
-11,747
-47% -$225K ﹤0.01% 972
2018
Q2 		$493K Buy
25,247
+208
+0.8% +$4.11K 0.01% 707
2018
Q1 		$470K Buy
25,039
+2,979
+14% +$64.4K 0.01% 715
2017
Q4 		$366K Buy
+22,060
New +$378K 0.01% 768

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.A. Davidson & Co's VYGR Position: Q4 2018 in Review

D.A. Davidson & Co sold out of Voyager Therapeutics (VYGR) in Q4 2018, closing a stake of 13,500 shares — an estimated $255K sold.

D.A. Davidson & Co first reported a position in VYGR in Q4 2017 and held it in 4 quarters. The position peaked at $493K in Q2 2018. 116 funds tracked by Wall St. Rank hold VYGR as of Q4 2018.

  • D.A. Davidson & Co reported no remaining Voyager Therapeutics position as of Q4 2018 after selling out during the quarter.
  • D.A. Davidson & Co sold 13,500 Voyager Therapeutics shares in Q4 2018, an estimated $255K.
  • D.A. Davidson & Co first reported a position in Voyager Therapeutics in Q4 2017 and held it in 4 quarters.
  • D.A. Davidson & Co's Voyager Therapeutics position peaked at $493K in Q2 2018.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2018.

Based on D.A. Davidson & Co's 13F filing for Q4 2018, filed 29 Jan 2019.